BRAF and melanoma: However, the majority of studies reporting immunosuppressive effects of BRAF mutations were done in melanoma and some additional evidence points to the absence of BRAF-mediated immunosuppression in the context of MSI CRCs: First, TIL density is not significantly reduced in BRAF-mutated MSI CRCs, compared to BRAF-wild-type MSI CRCs [106].